Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
ONCY(NASDAQ:ONCY) Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 2, 2025 /PRNewswire/ -- Cancer innovation is reaching new heights as the FDA approved breakthrough therapies for aggressive malignancies, including Modeyso for deadly brain tumors, while...
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
ONCY(NASDAQ:ONCY) Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating...
Oncolytics Biotech® Announces Upcoming Investor Conferences in September
ONCYSAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional...
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
ONCYUSA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the...
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
ONCYSAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of...
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
ONCYSAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily...
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going
ONCYUSA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study...
Oncolytics Names Jared Kelly CEO, Wayne Pisano Steps Down After Guiding Immunotherapy Progress
ONCYOncolytics Biotech To Present New Data From Phase I/II GOBLET Clinical Trial At 2025 ASCO Annual Meeting
ONCYHC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
ONCYJones Trading Downgrades Oncolytics Biotech to Hold
ONCYOncolytics Biotech Q1 EPS $(0.06) Beats $(0.09) Estimate
ONCYA Look at Oncolytics Biotech's Upcoming Earnings Report
ONCYOncolytics Biotech Annunces It Will Present New Data From Cohort 1 Of The Goblet Study At 2025 American Society Of Clinical Oncology Annual Meeting In Chicago May 30-June 3, 2025
ONCYReported Earlier, Oncolytics Biotech Secures Up To $20M In Flexible Funding For Pelareorep Development Through Share Purchase Agreement With Alumni Capital
ONCYRBC Capital Maintains Outperform on Oncolytics Biotech, Lowers Price Target to $5
ONCYOncolytics Biotech FY 2024 GAAP EPS C$(0.41) Beats C$(0.42) Estimate, Cash Position Of $15.9M Provides Runway Into Third Quarter 2025
ONCYOncolytics Biotech Continues To Make Good Progress In 2025 With Key Regulatory And Clinical Advancements, Reinforcing Pelareorep's Potential In Hard-to-treat Cancers
ONCYOncolytics Biotech Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
ONCYOncolytics Biotech Says Germany's Medical Regulatory Body, The Paul-Ehrlich-Institute (PEI), Has Approved The Continuation Of Patient Enrollment Into Cohort 5 Of The GOBLET Study
ONCYRBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target
ONCYHC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
ONCYA Preview Of Oncolytics Biotech's Earnings
ONCYOncolytics Biotech (NASDAQ:ONCY) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Oncolytics Biotech will report an earnings per share (EPS) of $-0.11.
Oncolytics Biotech, SOLTI Highlight Presentation Of New Clinical Biomarker Data Showing Pelareorep's Potential To Improve Prognosis Of Breast Cancer Patients At European Society For Medical Oncology
ONCY